The Priority Review

Clinical trials Brief

Takeda registers Phase 3b trial of Zasocitinib in psoriatic arthritis

Takeda plans to enroll 644 participants in a Phase 3b study of Zasocitinib (TAK-279) for active psoriatic arthritis, with a start date of January 11, 2027. The trial is expected to reach primary completion on April 18, 2030.

Primary source

ClinicalTrials.gov registry record, October 13, 2026

A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt)

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation